ENVB Latest Press Releases

-- November 4, 2026 --

Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study Business Wire 8:00 AM

-- October 21, 2026 --

Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies Business Wire 8:00 AM

-- September 15, 2026 --

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series Business Wire 8:00 AM

-- September 1, 2026 --

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference Business Wire 8:30 AM

-- August 14, 2026 --

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 Business Wire 4:05 PM

-- August 5, 2026 --

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003 Business Wire 8:00 AM

-- July 28, 2026 --

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development Business Wire 8:00 AM

-- June 29, 2026 --

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit Business Wire 8:00 AM

-- June 16, 2026 --

Enveric Biosciences Announces Participation in 2026 BIO International Convention Business Wire 9:28 AM

-- June 9, 2026 --

Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day Business Wire 8:00 AM

Market Data Delayed 15 Minutes